David Simpson

Robust quantification of the diamond nitrogen-vacancy center charge state via photoluminescence spectroscopy

Giannis Thalassinos, Daniel J. McCloskey, Alexander J. Healey, Charlie Pattinson et autres

Nitrogen vacancy (NV) centers in diamond are at the heart of many emerging quantum technologies, all of which require control over the NV charge state. Hence, methods for quantification of the relative photoluminescence (PL) intensities of the NV$^0$ and NV$^-$ charge state, …

Fluorescent emission of NV centers in diamond pillars embedded in optical fibers: optimization using a hybrid model

Wen Qi Zhang, Marco Capelli, Shuo Li, Brett C. Johnson et autres

Diamond-embedded optical fibers with negatively charged nitrogen-vacancy (NV) centers have great potential for remote and distributed magnetic field sensing. However, the magnetic field sensitivity of the currently proposed fiber configuration is limited. This work uses a numerical approach to investigate the effect …

au (code pays fourni par la source)

Contributors

Tusar Kanta Acharya, Gerard P. Ahern, Ammar Al-Omari, Jihyae Ann et autres

in, us, hu, kr, Éthiopie, de, se, gb, ar, fi, pt (code pays fourni par la source)

ASCEND-Eye

Emily L. Sammons, Georgina A. N. Buck, Louise J. Bowman, William M. Stevens et autres

PURPOSE: Preclinical studies support a protective role for omega-3 fatty acids (FAs) on diabetic retinopathy (DR), but these observations have not been confirmed in randomized trials. We present randomized evidence for the effects of omega-3 FAs on DR outcomes. DESIGN: A substudy …

gb (code pays fourni par la source)

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine Si Lun Tam, Mary Ann Anderson, Masa Lasica, Emma Verner et autres

Background: The combination of BCL2 and BTK inhibitors has shown synergistic activity. The combination of venetoclax, a BCL2 inhibitor, and ibrutinib, a BTK inhibitor, is an effective treatment for CLL/SLL. Sonrotoclax (BGB-11417) is a BH3 mimetic that binds and inhibits BCL2 with …

au, us, nz, es, it (code pays fourni par la source)

Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study

Alessandra Tedeschi, Chan Yoon Cheah, Stephen Opat, Emma Verner et autres

Background: Marginal zone lymphoma (MZL) is an uncommon type of non-Hodgkin lymphoma (NHL) that is generally considered incurable, with most patients experiencing a relapse after remission. Development of novel MZL therapies that are effective and tolerable is needed. Sonrotoclax (BGB-11417) is a …

it, au, es, us, cn (code pays fourni par la source)

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li et autres

BACKGROUND: We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second-line versus later-line. Here, we present an updated pooled analysis with a longer follow-up …

cn, au, nz, us (code pays fourni par la source)

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Chan Yoon Cheah, Constantine Si Lun Tam, Masa Lasica, Emma Verner et autres

Background/introduction: The effectiveness of Bcl-2 inhibitors as a treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was established by the approval of venetoclax in pts with CLL/SLL across all lines of therapy. However, the related adverse events (AEs) and emergence of BCL2 …

au, nz, cn (code pays fourni par la source)

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li et autres

Introduction: Zanubrutinib as an effective treatment option for mantle cell lymphoma (MCL) has been approved in the United States and China as monotherapy in patients with relapsed/refractory (R/R) MCL. We previously reported results of a pooled analysis of two zanubrutinib studies (BGB-3111-206 …

cn, au, nz, us (code pays fourni par la source)

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob Drobnyk Soumerai, Masa Lasica, Stephen Opat, Chan Yoon Cheah et autres

Background/introduction: The Bcl-2 inhibitor venetoclax has exhibited activity in pts with NHL in monotherapy (Clin Cancer Res 2021;27:4690-5) and in combination regimens (Blood 2019;133;1964-7). BGB-11417 is a highly selective Bcl-2 inhibitor with potency >10 times that of venetoclax in biochemical assays. BGB-11417 …

us, au, nz, es, it, cn (code pays fourni par la source)

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma

Kaja Kostyrko, Alex Lee, Marta Román, David Simpson et autres

us, es (code pays fourni par la source)

P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA

Stephen Opat, Chan Yoon Cheah, M. Lasica, Emma Verner et autres

Background: BCL2 is aberrantly expressed in many hematologic malignancies and promotes tumorigenesis by enabling cells to evade apoptosis. BCL2 inhibitors have an established role in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia. The currently approved BCL2 …

au, kr, nz, us, es, cn (code pays fourni par la source)